无偏lncRNA敲除CRISPR-Cas9筛选揭示RP11-350G8.5是多发性骨髓瘤的新治疗靶点
研究对多发性骨髓瘤(MM)细胞及其硼替佐米(BZB)耐药衍生细胞中的671个lncRNA进行无偏CRISPR-Cas9功能缺失筛选,结合患者预后与转录数据优先排序出8个对MM细胞适应度必需的致癌lncRNA。RP11-350G8.5在BZB耐药与否均最具前景,抑制后在体外和体内均显示抗肿瘤效应,并调控未折叠蛋白反应、诱导免疫原性细胞死亡,其结构分析提示可作为治疗靶点。
要点
- CRISPR-Cas9筛选671个lncRNA,结合患者数据优先排序出8个与高表达和不良预后相关的致癌lncRNA。
- RP11-350G8.5在BZB敏感和耐药MM细胞中均为最 promising 靶点,抑制后体外和体内均显示抗肿瘤效应。
- RP11-350G8.5敲除调控未折叠蛋白反应并诱导免疫原性细胞死亡,结构预测识别2个G四链体和3个发夹形成区域。
核心结论
- 研究提供关于MM中未探索lncRNA的创新见解,并将RP11-350G8.5确定为初治和BZB耐药MM患者的致癌治疗靶点。
研究设计与样本
- 对MM细胞及其硼替佐米(BZB)耐药衍生细胞中的671个lncRNA进行无偏CRISPR-Cas9功能缺失筛选。
- 设计并使用生物信息学优先排序流程,结合细胞筛选的功能数据与MM患者的预后和转录数据对候选lncRNA排序。
主要发现
- 优先排序出8个对MM细胞适应度必需的致癌lncRNA,与患者高表达和不良预后相关。
- RP11-350G8.5在BZB耐药与否均最具前景,抑制后在体外和体内均显示抗肿瘤效应。
- RP11-350G8.5敲除通过RNA测序和分子研究显示调控未折叠蛋白反应并诱导免疫原性细胞死亡。
- RNA荧光原位杂交表征RP11-350G8.5的胞质定位,生物物理实验预测其二维结构并识别2个G四链体和3个发夹形成区域。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is an incurable malignancy characterized by altered expression of coding and noncoding genes promoting tumor growth and drug resistance. Although the crucial role of long noncoding RNAs (lncRNAs) in MM is clearly established, the function of the noncoding RNAome, which might allow the design of novel therapeutics, is largely unknown. We performed an unbiased CRISPR-Cas9 loss-of-function screen of 671 lncRNAs in MM cells and their bortezomib (BZB)-resistant derivative. To rank functionally and clinically relevant candidates, we designed and used a bioinformatic prioritization pipeline combining functional data from cellular screens with prognostic and transcriptional data from patients with MM. With this approach, we unveiled and prioritized 8 onco-lncRNAs essential for MM cell fitness, associated with high expression and poor prognosis in patients with MM. The previously uncharacterized RP11-350G8.5 emerged as the most promising target, irrespective of BZB resistance. We (1) demonstrated the anti-tumoral effect obtained by RP11-350G8.5 inhibition in vitro and in vivo; (2) highlighted a modulation of the unfolded protein response and the induction of immunogenic cell death triggered by the RP11-350G8.5 knockout, via RNA sequencing and molecular studies; (3) characterized its cytoplasmic homing through RNA fluorescence in situ hybridization; and (4) predicted its 2-dimensional structure and identified 2 G-quadruplex and 3 hairpin-forming regions by biophysical assays, including thioflavin T, 1H nuclear magnetic resonance, and circular dichroism, to pave the way to the development of novel targeted therapeutics. Overall, we provided innovative insights about unexplored lncRNAs in MM and identified RP11-350G8.5 as an oncogenic target for treatment-naïve and BZB-resistant patients with MM.
引用
- Grillone K, Ascrizzi S, Cremaschi P, et al. An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma. Blood. 2024. PMID: 39158066. doi:10.1182/blood.2023021991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。